Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its novel antibody-drug conjugate (ADC), 9MW2921.
Next-Generation ADC Based on Mabwell’s IDDC Platform
9MW2921 is a next-generation ADC that leverages Mabwell’s innovative ADC technology platform, IDDC. This molecule is distinguished by its pharmaceutical characteristics, which include a stable structure, uniform composition, high purity, and ease of industrialization and amplification. These attributes make 9MW2921 a promising candidate in the field of targeted cancer therapies.
Preclinical Success and Anticipated Clinical Trials
Preclinical trials have demonstrated that 9MW2921 exhibits significant tumor-killing effects and controllable toxicity in animal models, along with a favorable safety and pharmacokinetics profile. These positive results support the advancement of 9MW2921 into clinical trials, where its efficacy and safety will be further evaluated in human subjects.-Fineline Info & Tech
